Abbvie Inc
NYSE:ABBV
EV/OCF
Enterprise Value to OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.
Market Cap | EV/OCF | ||||
---|---|---|---|---|---|
US |
Abbvie Inc
NYSE:ABBV
|
290.8B USD | 14.5 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
140.7B USD | 22.8 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.4B USD | 25.4 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.8B USD | 16.6 | ||
AU |
CSL Ltd
ASX:CSL
|
131.1B AUD | 34.9 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
82.4B USD | 12 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -77.6 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
39B USD | -9.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
27.6B USD | 21.6 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 25.7 | ||
KR |
Celltrion Inc
KRX:068270
|
36.7T KRW | 70.1 |
EV/OCF Forward Multiples
Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.